2-240873014-C-T
Variant summary
Our verdict is Pathogenic. Variant got 14 ACMG points: 14P and 0B. PM2PP3_StrongPP5_Very_Strong
The NM_000030.3(AGXT):c.560C>T(p.Ser187Phe) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0000197 in 152,172 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Likely pathogenic (★★).
Frequency
Consequence
NM_000030.3 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 14 ACMG points.
Transcripts
RefSeq
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
AGXT | ENST00000307503.4 | c.560C>T | p.Ser187Phe | missense_variant | Exon 5 of 11 | 1 | NM_000030.3 | ENSP00000302620.3 | ||
AGXT | ENST00000472436.1 | n.580C>T | non_coding_transcript_exon_variant | Exon 5 of 5 | 2 | |||||
AGXT | ENST00000476698.1 | n.297C>T | non_coding_transcript_exon_variant | Exon 2 of 4 | 5 |
Frequencies
GnomAD3 genomes AF: 0.0000197 AC: 3AN: 152172Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.00000400 AC: 1AN: 249728Hom.: 0 AF XY: 0.00 AC XY: 0AN XY: 135090
GnomAD4 exome Cov.: 31
GnomAD4 genome AF: 0.0000197 AC: 3AN: 152172Hom.: 0 Cov.: 32 AF XY: 0.0000135 AC XY: 1AN XY: 74330
ClinVar
Submissions by phenotype
Primary hyperoxaluria, type I Pathogenic:4Other:1
- -
- -
- -
- -
- -
Primary hyperoxaluria Pathogenic:1
Variant summary: AGXT c.560C>T (p.Ser187Phe) results in a non-conservative amino acid change located in the Aminotransferase class V domain (IPR000192) of the encoded protein sequence. Five of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 4e-06 in 249728 control chromosomes. The available data on variant occurrences in the general population are insufficient to allow any conclusion about variant significance. c.560C>T has been reported in the literature in both compound heterozygous and homozygous individuals affected with Primary Hyperoxaluria Type 1 (e.g., Minatogawa_1992, Hoppe_1997, Hoyer-Kuhn_2014, Williams_2015), and the variant has been shown to segregate with disease in related individuals. These data indicate that the variant is likely to be associated with disease. Several publications report experimental evidence evaluating an impact on protein function, finding that the variant disrupts the enzyme active site and results in <10% of normal enzymatic activity (e.g., Oppici_2013, Coulter-Mackie_2006, Minatogawa_1992). The following publications have been ascertained in the context of this evaluation (PMID: 16971151, 9002528, 24385516, 1301173, 23589421, 25629080). One submitter has reported clinical-significance assessments for this variant to ClinVar after 2014 and has classified the variant as likely pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at